Presentation description

The majority of PDAC cases arise from mutations in KRAS, a GTPase involved in the MAP Kinase (MAPK) pathway. Inhibition of the MAPK pathway upregulates autophagy, a process in which cells recycle their intracellular components to sustain nutrient demands under stressful conditions and can render targeted therapies ineffective. . We are searching for drugs that are FDA-approved or in clinical trials and modulate autophagy for potential repurposing in novel combinations.